Overview

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Status:
ENROLLING_BY_INVITATION
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
A Phase 2 Open-label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of AOC 1020 Administered Intravenously to Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)
Phase:
PHASE2
Details
Lead Sponsor:
Avidity Biosciences, Inc.